Day: June 18, 2024

CARBIOS Tomra Textiles(L-R) Mathieu BERTHOUD, Strategic Sourcing Director, CARBIOS; Vibeke KROHN, Head of TOMRA Textiles;Emmanuel LADENT, CEO, CARBIOS; Mari Larsen SÆTHER, Recycling Lead, TOMRA TextilesCARBIOS and TOMRA Textiles will collaborate to close the textiles circularity gap between collection of textile waste and innovative technologies for textile-to-textile recycling Oslo/Clermont-Ferrand, Tuesday 18 June 2024 (6.45am CEST): CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, and TOMRA Textiles, a tech venture set up by sorting technology leader TOMRA (Oslo Stock Exchange: TOM.OL), announce the signing of an agreement to collaborate on establishing an efficient stream in Northern Europe from textile...

Innovative system offers two rows of seats on long rails with a fully rotating front row Flexible layout for more in-cabin space Award showcases local R&D, complete technology development, and production readinessAURORA, Ontario, June 18, 2024 (GLOBE NEWSWIRE) — For more than 65 years, Magna has helped redefine the very concept of consumer experience and design in the vehicle. Today, the company has further advanced traditional in-cabin vehicle design with its first awarded contract to deliver a reconfigurable seating system to a Chinese OEM. This innovative technology offers fully rotating front seats paired with long rails, enabling a flexible layout for more in-cabin space. Magna’s reconfigurable seating system allows the vehicle to adapt to the consumer, instead of forcing the consumer to adapt to the vehicle. The integration...

TORONTO, June 17, 2024 (GLOBE NEWSWIRE) — Sulliden Mining Capital Inc. (TSX: SMC) (“Sulliden” or the “Company”) is pleased to announce that Indivar Pathak has been appointed as a director of the Company, effective immediately. The appointment of Mr. Pathak follows the resignation of Peter Hooper as a director of the Company. The board and management of Sulliden express their gratitude to Mr. Hooper for his efforts and contributions and wish him well in his future endeavours. About Sulliden Sulliden is a mining company focused on acquiring and advancing brownfield, development-stage, and early production-stage mining projects. Sulliden Mining Capital Inc.On behalf of the Board“Scott Moore”, Chief Executive Officerinfo@sulliden.com(416) 861-2267 THE TSX HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OF THIS...

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (Nasdaq: AMCX) (the “Company” or “AMC Networks”) today announced the pricing of $125 million aggregate principal amount of 4.25% convertible senior notes due 2029 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering of the notes, the Company has granted the initial purchasers an option to purchase, for settlement within a 13-day period beginning on, and including, the first day on which the notes are issued, up to an additional $18.75 million aggregate principal amount of the notes. The offering of the notes is expected to close on June 21, 2024, subject to satisfaction of customary closing conditions. AMC Networks...

Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s Disease MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) — CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients, and positively affect neurons of the midbrain. MC1R is known to be a key receptor in brain and skin cells. In large studies, it was found that fair-skinned patients have a higher risk of PD associated with a malfunctioning MC1R.a, 1-2 Since afamelanotide is known to optimise the function of the MC1R, it is hypothesised that the drug treatment...